Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Oral Oncol. 2019 Oct 10;98:147–155. doi: 10.1016/j.oraloncology.2019.09.005

Figure 4.

Figure 4.

MYB inhibitors suppress ACC viability in vitro and in vivo. (a) Immunoblot analysis testing efficiency of MYB depletion with PLKO.1 control and three different lentiviral MYB shRNAi clones. (b) Viability of UFBT and UFH2 cell lines after transduced with control or MYB shRNA lentiviruses (error bars represent standard deviation of UFBT (n=3 experiments) or UFH2 (n=5 experiments). (c) 2x10^6 ACCX22 (left) or UFH1PDX (right) cells were treated with shMYB or control and injected subcutaneously to dorsal flanks of NOD/SCID mice. ACCX22 PDX (left; n=3 mice control and n=3 mice shMYB), UFH1PDX (right; n=3 mice control and n=6 mice shMYB). Error bars represent median and standard deviations.